Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1521

Sort by

Sort Order Select

Journal Articles

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

Blood (2020) 135 (19): 1696–1703.

https://doi.org/10.1182/blood.2019003347

Published: 2020

Includes: Supplemental data

Journal Articles

Description of a knock-in mouse model of JAK2 V617F MPN emerging from a minority of mutated hematopoietic stem cells

Olivier Mansier, Badr Kilani, Amélie V. Guitart, Alexandre Guy, Virginie Gourdou-Latyszenok, Caroline Marty, Marie Parrens, Isabelle Plo, William Vainchenker, Chloé James

Blood (2019) 134 (26): 2383–2387.

https://doi.org/10.1182/blood.2019001163

Published: 2019

Includes: Supplemental data

Journal Articles

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Blood (2019) 134 (26): 2388–2398.

https://doi.org/10.1182/blood.2019001385

Published: 2019

Includes: Supplemental data

Journal Articles

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Murtadha Al-Khabori, MD, Shoaib Al-Zadjali, PhD, Iman Al Noumani, Khalil Al Farsi, Salam Al-Kindi, MD, Mohamed Al Huneini, MD, Naglaa Fawaz, MBBChir, MMSc, PhD, Al Lamki Sulayma, MD, Mahdiya Pir Al Bulushi, MD FRCPC, Khalid Al Hashmi, MD, Muna Al Tarshi, MD, Muhanna Almusalhi

Blood (2019) 134 (Supplement_1): 5383.

https://doi.org/10.1182/blood-2019-128309

Published: 2019

Journal Articles

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Ivy Altomare, MD, Anna Nguyen, PharmD, MPH, Shreekant Parasuraman, BPharm, PhD, Dilan Paranagama, PhD, Jonathan K. Kish, PhD MPH, Kevin Lord, PhD MHS, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 4192.

https://doi.org/10.1182/blood-2019-127442

Published: 2019

Journal Articles

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Claire N Harrison, Professor, Aaron T. Gerds, MD MS, Jean-Jacques Kiladjian, MD PhD, Konstanze Döhner, Sarah A Buckley, MD, Jennifer A. Smith, PhD, Adam R Craig, MD PhD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4175.

https://doi.org/10.1182/blood-2019-129245

Published: 2019

Journal Articles

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Blood (2019) 134 (Supplement_1): 4238.

https://doi.org/10.1182/blood-2019-126967

Published: 2019

Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 4168.

https://doi.org/10.1182/blood-2019-123546

Published: 2019

Journal Articles

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Allison Pike, RN, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 5906.

https://doi.org/10.1182/blood-2019-127272

Published: 2019

Journal Articles

Population Pharmacokinetic Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma or Acute Myeloid Leukemia

Shu Chin Ma, PhD, Russ Wada, PhD, Martine Allard, PhD, Greg Slatter, PhD

Blood (2019) 134 (Supplement_1): 5766.

https://doi.org/10.1182/blood-2019-131331

Published: 2019

Journal Articles

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Kelly L. Schoenbeck, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Andrew D. Leavitt, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Rebecca L. Olin, MD, Giselle Salmasi, MD, Peter H. Sayre, MD PhD, Neil P. Shah, MD PhD, Anand Dhruva, MD, Chloe E. Atreya, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 5859.

https://doi.org/10.1182/blood-2019-129638

Published: 2019

Journal Articles

Outcomes of Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis: A Single Institution Experience

Sajjad Akbar Bhatti, MBBS, Abdulraheem Yacoub, MD, Anurag K. Singh, MD

Blood (2019) 134 (Supplement_1): 5740.

https://doi.org/10.1182/blood-2019-129505

Published: 2019

Journal Articles

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Thomas G. Knight, MD, Myra Robinson, MS, Jing Ai, MD PhD, Brittany K Ragon, MD, Rhonda Davis, RN, BSN, Cindy Shiflett, LPN, Erica Ruston, RN, BSN, Hailey Glover, RN, BSN, Jigar Trivedi, MSc, PharmD, Belinda R Avalos, MD, Jonathan M. Gerber, MD, James T Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2019) 134 (Supplement_1): 2099.

https://doi.org/10.1182/blood-2019-128858

Published: 2019

Journal Articles

Hematological Disorders in Human Patients with Son Mutations

Lana Vukadin, Jung-Hyun Kim, PhD, Tara Bly Hackwelder, Nathan Ungerleider, PhD, Erik Flemington, Eun-Young Erin Ahn, PhD

Blood (2019) 134 (Supplement_1): 3709.

https://doi.org/10.1182/blood-2019-130616

Published: 2019

Journal Articles

Molecular Analysis in Patients with Idiopathic Erythrocytosis

Katarzyna Aleksandra Jalowiec, Naomi A. Porret, PhD, Raphael Joncourt, Alicia Rovo

Blood (2019) 134 (Supplement_1): 2230.

https://doi.org/10.1182/blood-2019-128169

Published: 2019

Journal Articles

Single-Cell RNA-Seq to Assess Differential Responses to Tnfα in Human Hematopoietic Stem and Progenitor Cells in Myeloproliferative Neoplasm

Brianna Craver, MS, Quy Nguyen, Gajalakshmi Ramanathan, PhD, Angela G. Fleischman, MD PhD

Blood (2019) 134 (Supplement_1): 2518.

https://doi.org/10.1182/blood-2019-123480

Published: 2019

Journal Articles

Clinical Features of Children with Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in Japan: Retrospective Nationwide Survey

Hisashi Ishida, MD PhD, Takeo Sarashina, MD PhD, Risa Matsumura, Katsutsugu Umeda, MD, PhD, Tetsuo Mitsui, MD PhD, Naoto Fujita, MD PhD, Daisuke Tomizawa, MD PhD, Kevin Y Urayama, PhD MPH, Yasushi Ishida, MD PhD, Takashi Taga, MD PhD, Masatoshi Takagi, MD PhD, Souichi Adachi, MD PhD, Atsushi Manabe, MD PhD, Toshihiko Imamura, MD PhD, Katsuyoshi Koh, MD, Akira Shimada, MD PhD

Blood (2019) 134 (Supplement_1): 2958.

https://doi.org/10.1182/blood-2019-123429

Published: 2019

Journal Articles

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Keiji Minakawa, Koki Ueda, MD PhD, Osamu Nakajima, Tetsuro Yokokawa, MD, Yusuke Kinishima, MD, Tomofumi Misaka, MD PhD, Kazuei Ogawa, MD PhD, Takayuki Ikezoe, MD PhD, Yasuchika Takeishi, MD PhD, Kazuhiko Ikeda, MD PhD

Blood (2019) 134 (Supplement_1): 2964.

https://doi.org/10.1182/blood-2019-124575

Published: 2019

Journal Articles

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

Tobias Ronny Haage, MD, Andreas Johann Müller, Priyadharshini Arunachalam, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2965.

https://doi.org/10.1182/blood-2019-122660

Published: 2019

Journal Articles

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Peter Müller, PhD, Bärbel Edelmann-Stephan, PhD, Fabian Richter, PhD, Klaus Pfizenmaier, PhD, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2966.

https://doi.org/10.1182/blood-2019-127997

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

Description of a knock-in mouse model of JAK2 V617F MPN emerging from a minority of mutated hematopoietic stem cells

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Population Pharmacokinetic Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma or Acute Myeloid Leukemia

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Outcomes of Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis: A Single Institution Experience

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Hematological Disorders in Human Patients with Son Mutations

Molecular Analysis in Patients with Idiopathic Erythrocytosis

Single-Cell RNA-Seq to Assess Differential Responses to Tnfα in Human Hematopoietic Stem and Progenitor Cells in Myeloproliferative Neoplasm

Clinical Features of Children with Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in Japan: Retrospective Nationwide Survey

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only